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We have read with interest the letter written by Dr. Taya-
saheb Patil about our article on “Prehypertension in young
female, where they stand?”
The comments made in their letter to Editor are valid and
welcome and contribute to our understanding of the
phenomenon. However, the scope of our study as mentioned
in methods is restricted to studying blood pressure response
to tread mill test among prehypertensive female subjects
along with other phenotypes. We chose this parameterFig. 1 e Individual and pooled (95% Confidence Interval, 95% CI
curve (AUC) of pregnancy-associated plasma protein A (PAPP-Alooking at the scope of study and feasibility. By no means it is
intended to replace in any manner other well-known risk
factors. At best this could be one more variable that may be
used to stratify the population further based on their response
to stress like tread mill.
Sanjay Kumar Diwan
E-mail address: drskdiwan79@rediffmail.com
DOI of original article: http://dx.doi.org/10.1016/j.ihj.2012.10.004Pregnancy-associated plasma protein A (PAPP-A) for the early
diagnosis of myocardial infarction: More doubts than
certaintiesWe readwith interest the recent article of Gururajan et al, who
concluded that pregnancy-associated plasma protein A (PAPP-
A) seems to be a promising biomarker for identification and
risk stratification for patients with ischemic heart disease.1 In
particular, this promising biomarker exhibited an area under
the Receiver Operator Characteristics (ROC) curve (AUC) that
was even higher than that of troponin I (i.e., 0.904 versus 0.765)
in patients admitted to emergency care unit.
PAPP-A is a high-molecular-mass glycoprotein, which is
mainly synthesized by the syncytiotrophoblast and has orig-
inally been proposed for the screening of Down syndrome. In
2001, however, Bayes-Genis et al first suggested that PAPP-A
may be a promising candidate biomarker of ischemic heart
disease, reporting an AUC of 0.94 for discriminating patientswith acute myocardial infarction (AMI) from those without
ischemic heart injury.2 Since major controversy still exists on
the clinical usefulness of PAPP-A for the early diagnosis of
AMI, we carried out an electronic search on PubMed, Thomson
and Scopus to retrieve scientific articles that have assessed
PAPP-A in the diagnostics of ischemia heart disease by using
the keywords “myocardial infarction” or “ischaemic heart
disease”, “diagnosis”, “troponin”, and “PAPP-A” or “preg-
nancy-associated plasma protein A”. The references were
systematically assessed for quality by two authors (GL and GC)
according to the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS) checklist criteria, and searched for addi-
tional studies on this topic. After reading of abstract and text,
only those studies comparing the diagnostic performance of) Area Under the Receiver Operator Characteristics (ROC)
) for early diagnosis of ischemic heart disease.
i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 6 2 4e6 2 7626PAPP-A with that of a cardiospecific troponin assay were
considered eligible for meta-analysis. Potential discrepancies
between authors were solved by CM.
Five studies, totalling 2050 patients (1333 cases and 717
controls), met our inclusion criteria (I-squared heterogeneity,
82%).1,3e6 Interestingly, the cumulativeAUC for troponin alone
was marginally but still significantly higher (0.85; 95% CI,
0.78e0.92) than that of PAPP-A alone (0.67; 95% CI, 0.54e0.80;
p ¼ 0.03) (Fig. 1). Pooled data about sensitivity and specificity
could not be calculated, since these were not provided in all
studies. In the only one study comparing troponin alone with
the combination of troponin and PAPP-A, the AUC obtained
with the two biomarker approach was marginally but not
significantly improved (i.e., 0.955 versus 0.952; p ¼ 0.42).6
Taken together, the results of this meta-analysis including
2050 patients with ischemic heart disease suggest that PAPP-A
may not be useful in the early diagnosis of AMI as a stand
alone test, whereas further studies should be planned to
establish its diagnostic accuracy in combination with a car-
diospecific troponin immunoassay.r e f e r e n c e s
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To the Editor,
We have read with interest the letter written by Dr. Giuseppe
Lippi about our article on “Pregnancy-associated plasma
proteinA (PAPP-A)”. Dr. Lippi has concluded that PAPP-A alone
cannot be used as amarker for diagnosis of acuteMI and it has
to be used in combination with tropnin and we have also
concluded the same. Area Under the time concentration
Curve (AUC) for discrimination between ischemic and non-ischemic subsets improved only when PAPP-A was used in
combination with tropnin and CK-MB.
Prema Gurumurthy
Director e Academics, FLL Hospital and
Dr K M Cherian Heart Foundation, India
E-mail address: prema.fll@gmail.com
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generator destructive-replacement for lead-pin/lead-port clip
aperture misalignment
Medtronic introduced low-cost Champion VVI pacing devices
for use in countries such as India a few years ago and were
subsequently withdrawn. These devices are still being
encountered when patients with devices present themselves
for battery replacement. Figures 1 and 2 show the method of
finger pressure application over the implantable pulse
generator (IPG) header in order to align the pair of apertures
for correct lead-pin insertion or removal and Figure 3 depictsa correctly engaged lead-pin. Although very simple in design
we describe a problem faced at pacemaker IPG replacement
due to lead-pin misalignment in the lead-port.
A 52-year-old patient implanted with such a VVI pace-
maker (Model no, 8079, SN PGE005827C) in 2003 was found to
have a stuck lead-pin in the IPG lead-port due to misalign-
ment with the second (deeper) of the two holes present in
the self-retaining spring clip of the lead-port at IPG
